09/10/2024 | Press release | Archived content

First in Human Phase I Dose Escalation Study of ALG.APV 527, a 5T4 Tumor Antigen Conditional 4 1BB Bispecific Antibody, in Patients with Advanced Solid Tumors, Demonstrates[...]

Please select the service you want to use:

• Newsvine
• Digg
• Delicious
• StumbleUpon
• Technorati
• Buzz
• Favorites
• Google Reader

 Back

 Download the original document